WALTHAM, MA, USA I August 18, 2025 I Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for ...

YANTAI, China I August 18, 2025 I RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today ...

SEOUL, South Korea I August 18, 2025 I Avixgen, a subsidiary of Dx&Vx, announced on the 18th that it has signed a licensing-out agreement worth ...

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global ...

NEEDHAM, MA, USA I August 18, 2025 I Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment ...

NEWPORT BEACH, CA, USA I August 18, 2025 I jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study ...

RESEARCH TRIANGLE PARK, NC, USA I August 18, 2025 I Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ...

Melanocortin receptor agonists offer a promising, differentiated mechanism that targets key drivers of retinal diseases, including DR.

HANGZHOU, China I August 18, 2025 I Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying ...

SAN DIEGO, CA, USA I August 18, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...